Warsaw, Mazowieckie, Poland, October 2025 — Polpharma Group, one of the largest pharmaceutical organizations in Central and Eastern Europe and Central Asia, has announced a planned leadership transition. Markus Sieger, who has successfully led the Group for the past decade, will conclude his term as CEO on January 1, 2026, as part of a long-planned succession. He will continue to contribute to the company’s strategic development as a member of the Supervisory Board.
Under Markus Sieger’s leadership, Polpharma Group achieved substantial financial growth and organizational transformation, staying true to its mission: “We help people live healthily in a healthy world.” The company has strengthened its position as a trusted partner to healthcare systems across Europe and Central Asia, consistently delivering high-quality, affordable medicines to millions of patients.
“On behalf of the entire Polpharma community, I sincerely thank Markus for his exceptional commitment and visionary leadership over the past decade,” said Jerzy Starak, Owner of Polpharma Group. “His actions have played a key role in guiding the company through a dynamically changing and challenging environment, strengthening our values and setting a strategic direction for the future. I am pleased that Markus will remain part of our team as a member of the Supervisory Board.”
Sebastian Szymanek to Lead the Next Chapter
Effective January 1, 2026, Sebastian Szymanek, currently serving as President of Zakłady Farmaceutyczne Polpharma SA, will take over as President of Polpharma Group.
With nearly 30 years of experience in the pharmaceutical industry, Szymanek has a strong background spanning both generic and innovative markets. He joined Polpharma in 2007 and has since held multiple leadership roles in the commercial division, including General Director in Poland (2014) and President of the Management Board of Polpharma Trade Office (2017–2021). Since September 2021, he has led Polpharma SA as President, driving strategic transformation, cross-functional collaboration, and global market expansion.
“I am convinced that Sebastian is the best person to lead the Polpharma Group to the next stage of its development,” said Nick Haggar, Chairman of the Supervisory Board. “His in-depth knowledge of the organization, strong leadership skills, focus on operational efficiency, and unwavering commitment to our mission make him the ideal choice to lead the Group’s continued growth and innovation.”
About Polpharma Group
Founded over 90 years ago, Polpharma Group is a leading regional pharmaceutical manufacturer operating across Central and Eastern Europe, the Caucasus, and Central Asia. Its portfolio includes modern medicines, active ingredients, and innovative healthcare solutions. Each year, Polpharma produces over 400 million packages of drugs, distributed in more than 40 countries through its own network and partnerships.
The Group’s operations span several key companies, including Zakłady Farmaceutyczne Polpharma SA (Poland), Zakłady Farmaceutyczne Santo (Kazakhstan), Farmaprojects (Spain), 089Farm (Germany), and Swiss Pharma International (Switzerland). Polpharma Group employs over 5,600 professionals dedicated to improving patient health worldwide.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
